BOSTON, Massachusetts, May 23, 2024 – Today, S2N Health, Inc. announced it successfully secured seed funding to fuel the growth of the company’s RepSignalTM medtech customer intelligence SaaS platform, and to develop a robust roadmap of AI-powered solutions for accelerating the market impact of healthcare technologies. The round was led by Excelerate Health Ventures, a premier digital health fund focused on healthcare software and technology-enabled services, with participation from other established healthcare and technology investors, including Boston Millennia Partners and Robin Hood Ventures.
S2N Health has expanded its Board of Directors, adding seasoned medtech entrepreneur and executive Martha Shadan who has more than three decades of experience in the life science industry as a business leader in a variety of large and start-up organizations. “Having benefitted from the talent, expertise, and analytics capabilities of the S2N Health team, I am thrilled to participate in this next chapter of the company’s growth as a software and data-enabled solutions provider,” says Martha Shadan. She will join Andrew Schwab, Managing Partner of Excelerate Health Ventures, and Ren Roome, Partner at Boston Millenia Partners on the S2N Health Board.
This seed funding round follows the impressive market traction of RepSignal across a range of large and emerging medtech companies. This success is fueled by S2N Health’s unique combination of deep industry experience, rich multi-source data, and powerful analytics. RepSignal’s best-in-class CRM integration aligns sales and marketing teams on high-value opportunities for precision customer targeting, engagement, and resource planning. “Years of advising medtech companies revealed to us that many have a wealth of data, but struggle to deploy it effectively, especially within their commercial teams,” says Co-Founder and Chief Executive Officer Amy Siegel. “RepSignal bridges this gap, transforming complex data into actionable insights that empower field teams and streamline processes.”
“S2N Health is positioned to become the premier platform that transforms the entire commercial process for medtech companies, with the potential to expand into other healthcare verticals and applications,” says Andrew Schwab, Managing Partner at Excelerate Health Ventures. “We are excited to be working S2N Health’s experienced leaders Amy Siegel and Tim Kofol (CTO), as well as the highly skilled professionals who have built the company to where it is today.”
About S2N Health
Established in 2011, S2N Health accelerates go-to-market strategies and growth through value-maximizing SaaS solutions and data-enabled services for healthcare technology companies. In 2021, S2N Health launched RepSignal—an AI-powered SaaS platform that uses advanced analytics and AI to transform complex data into actionable insights for medtech commercial teams and other stakeholders. RepSignal provides effective end-to-end solutions for any stage in the commercial lifecycle, either delivered on a stand-alone web platform or seamlessly integrated into Salesforce and other CRMs. RepSignal is available on the Salesforce AppExchange. For additional information about S2N Health and RepSignal, please visit s2nhealth.com.
Media Contact
Please direct media inquiries to Kathrin Schlenzig at Iota Marketing Group.
